Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned an average rating of "Buy" from the eleven ratings firms that are covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $45.13.

Several research firms have recently commented on DNTH. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an "overweight" rating for the company. Oppenheimer initiated coverage on Dianthus Therapeutics in a research report on Thursday, October 3rd. They set an "outperform" rating and a $48.00 price target on the stock. Baird R W upgraded Dianthus Therapeutics to a "strong-buy" rating in a research report on Friday, July 26th. Finally, Robert W. Baird initiated coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They set an "outperform" rating and a $58.00 price objective for the company.

Dianthus Therapeutics Stock Down 2.9 %

NASDAQ:DNTH traded down $0.82 during trading hours on Friday, reaching $27.50. 373,696 shares of the stock were exchanged, compared to its average volume of 196,107. The stock has a market capitalization of $807.10 million, a P/E ratio of -4.72 and a beta of 1.85. The firm has a 50 day simple moving average of $27.77 and a 200-day simple moving average of $26.12. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. As a group, analysts expect that Dianthus Therapeutics will post -2.28 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hussman Strategic Advisors Inc. bought a new position in Dianthus Therapeutics in the 1st quarter valued at about $630,000. Vanguard Group Inc. boosted its holdings in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after acquiring an additional 384,182 shares in the last quarter. StemPoint Capital LP acquired a new position in shares of Dianthus Therapeutics during the first quarter valued at approximately $1,304,000. Bain Capital Life Sciences Investors LLC bought a new stake in Dianthus Therapeutics during the first quarter worth approximately $89,761,000. Finally, Janus Henderson Group PLC bought a new stake in Dianthus Therapeutics during the first quarter worth approximately $11,251,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.